Clinical–Patient Studies

Journal of Neuro-Oncology

, Volume 82, Issue 1, pp 91-93

First online:

A lipoxygenase inhibitor in breast cancer brain metastases

  • D. F. FlavinAffiliated withFoundation for Collaborative Medicine and Research Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The complication of multiple brain metastases in breast cancer patients is a life threatening condition with limited success following standard therapies. The arachidonate lipoxygenase pathway appears to play a role in brain tumor growth as well as inhibition of apoptosis in in-vitro studies. The down regulation of these arachidonate lipoxygenase growth stimulating products therefore appeared to be a worthwile consideration for testing in brain metastases not responding to standard therapy. Boswellia serrata, a lipoxygenase inhibitor was applied for this inhibition. Multiple brain metastases were successfully reversed using this method in a breast cancer patient who had not shown improvement after standard therapy. The results suggest a potential new area of therapy for breast cancer patients with brain metastases that may be useful as an adjuvant to our standard therapy.


Cancer Lipoxygenase Boswellia serrata Oxidoreductase inhibitor LOX inhibitors Lipoxygenase inhibitor Brain Cancer Breast Cancer Metastases Breast Cancer Remission Arachidonate: Oxygen oxidoreductase Herceptin